ARTICLE · CARDIAC SAFETY & IBOGA
Ibogaine is moving into clinical trials. The cardiac questions haven’t moved with it.
An emergency nurse’s guide to QT, CYP2D6, and the questions every facilitator and journeyer should be asking — written for the new regulatory landscape.
By April Louise Persephone, RN · 32 years emergency medicine
In late April 2026, two things happened in the same week. On April 18, the White House signed an executive order directing the FDA and DEA to accelerate review of psychedelic compounds, with ibogaine specifically named in the order. On April 24, the FDA cleared the first US clinical study of an ibogaine-derived treatment for alcohol use disorder.
I work in the world of plant medicine and harm reduction. I am also a nurse who spent thirty-two years in emergency departments. When I see ibogaine moving toward the clinical mainstream, I feel two things at once. The first is gratitude — for people facing opioid use disorder and PTSD, ibogaine has produced clinical results that other medicines have not. The second is concern — because the regulatory timeline is moving faster than the cardiac safety conversation, and the people most likely to seek out this medicine in the next twelve months are not the participants in monitored clinical trials. They are people sitting in retreat centers, in private homes, in community ceremonies, often without anyone in the room who has read an EKG before.
This piece is for those people, and for the facilitators who serve them. I want you to walk in knowing what your heart is being asked to do.
THE PHARMACOLOGY
What ibogaine actually does.
Ibogaine is the principal psychoactive alkaloid in Tabernanthe iboga, a shrub native to Central Africa. In ceremonial contexts, it has been used for generations by Bwiti practitioners. In clinical contexts, it has shown remarkable ability to reduce cravings and withdrawal symptoms in people with opioid and stimulant use disorders, often after a single administration.
It also produces a long, intense, often physically demanding journey — typically twelve to thirty-six hours — and during that journey, it does something to the heart that no other psychedelic does in the same way.
It prolongs the QT interval. Of all the medicines on this site, this is the only one I would insist on a 12-lead EKG before sitting with — every time, no exceptions.
THE PHYSIOLOGY
The QT interval, in plain English.
Every heartbeat is an electrical event. A wave of electricity sweeps through the upper chambers, then the lower chambers, then the heart resets and waits for the next signal.
The QT interval is the time it takes for the lower chambers — the ventricles, the workhorses of your circulation — to complete one electrical cycle and reset. It begins when the ventricles start to depolarize and ends when they finish repolarizing. On an EKG tracing, it is the distance from the start of the QRS complex to the end of the T wave.
A normal QT interval, corrected for heart rate (the “QTc”), is generally under 450 milliseconds in men and under 460 milliseconds in women. When the QT lengthens past about 500 milliseconds, the risk of a particular arrhythmia called torsades de pointes — a rapid, chaotic ventricular rhythm — increases sharply.
Torsades de pointes can stop the heart.
This is not a theoretical risk in the ibogaine literature. It is the risk. The cardiac deaths reported with iboga have largely come from this exact mechanism: a prolonged QT interval that crossed into arrhythmic territory in someone whose heart had not been checked beforehand.
THE MECHANISM
Why ibogaine prolongs the QT.
In the cardiac muscle cell, repolarization depends on potassium flowing out through specific channels. The most important of these for QT physiology is called the hERG channel (sometimes written IKr).
Ibogaine and its primary metabolite, noribogaine, both block hERG channels. When you slow the outward potassium current, you slow repolarization, which lengthens the QT.
This is not a quirky side effect. It is part of how the drug interacts with cardiac tissue, and it is dose-dependent. The higher the plasma concentration, the more pronounced the QT prolongation. And because noribogaine has a long half-life — measured in days, not hours — the prolongation can persist long after the journey ends.
A 2026 scoping review in Molecules summarized the cardiac safety picture this way: clinical translation of ibogaine remains substantially constrained by unresolved cardiac risk, even as novel structural congeners (oxa-iboga compounds, 18-MC) are being developed specifically to retain anti-addictive efficacy without the hERG block.
In other words, the field knows the heart problem. The field is working on it. But the iboga most people are sitting with today is the same iboga that has been associated with cardiac deaths for decades.
THE STANDARD OF CARE
What “monitored” should mean.
When I talk about monitoring, I am not being dramatic. I mean the same standard of care a hospital uses when administering any QT-prolonging IV medication.
A monitored ibogaine setting should include:
- A 12-lead EKG before administration, read by someone trained to read one. This is not optional. A pre-treatment QTc gives the baseline against which everything else is measured.
- Continuous cardiac telemetry during the dosing window and for hours afterward. The patient is connected to a monitor; someone watches the rhythm strip; alarms are set for QTc thresholds and rhythm changes. This is what a hospital tele unit does for any patient on a QT-prolonging drug.
- Functioning emergency equipment in the room. A defibrillator. IV access. Magnesium sulfate available — it is the first-line treatment for torsades de pointes. A clinician with ACLS or equivalent training within reach, not down the hall.
- A medication and electrolyte review. Real, comprehensive, current. Not a one-line intake form. Recent labs for potassium, magnesium, and calcium are appropriate.
- A post-treatment monitoring window. Because of noribogaine’s long half-life, QT prolongation can persist for days. Discharge planning needs to account for that.
The St. Kitts cohort published by Dr. Deborah Mash and colleagues — 191 patients on continuous EKG telemetry with CYP2D6 genotyping — saw transient QT prolongation that returned to baseline, with no clinically significant arrhythmias, hospitalizations, or deaths. That is what proper monitoring looks like, and the safety record reflects it. The deaths reported in the literature have largely come from settings that did not look like that.
WHAT TO ASK A FACILITATOR
Questions to bring to any facilitator.
If you are considering an iboga or ibogaine ceremony, here is what I would ask, in plain language:
- Will I have a 12-lead EKG before the ceremony, and will a clinician read it?
- Will I be reviewed for medications that prolong the QT interval, including methadone, certain antidepressants, antibiotics, and antifungals?
- Will I have current labs for potassium, magnesium, and calcium?
- Will I be screened for personal or family history of cardiac arrhythmias or sudden cardiac death?
- Will I be on continuous cardiac monitoring during and after dosing?
- Is there functioning emergency equipment in the room — a defibrillator, IV access, IV magnesium sulfate?
- Who in the room is trained in ACLS or equivalent, and how quickly can emergency services reach us if needed?
- What is the post-treatment monitoring plan, given that noribogaine’s effects on the heart can persist for days?
A facilitator who takes ibogaine seriously will welcome these questions. A facilitator who deflects them, dismisses them, or tells you that “the medicine takes care of you” is telling you something important about what kind of room you are about to walk into.
I am not telling you that ibogaine is too dangerous to consider. I am telling you that the level of preparation you would expect for any other QT-prolonging medical treatment is the level of preparation you should expect for this one.
THE NEW LANDSCAPE
What the new regulatory landscape changes — and what it doesn’t.
The April 18, 2026 executive order accelerated federal review of psychedelic compounds and named ibogaine specifically. The FDA cleared the first US ibogaine clinical trial. The DEA increased production quotas. There is real momentum, and that momentum will produce more rigorous data, more standardized protocols, and — eventually — modified compounds like oxa-iboga and 18-methoxycoronaridine that may carry the therapeutic benefit without the cardiac shadow.
What the regulatory motion has not changed: the cardiac physiology of the iboga most people will sit with in 2026. That has not moved. The hERG channel still blocks. The QT still prolongs. The same medications, electrolytes, and genetic factors still matter. A federal headline does not screen your heart.
If anything, the next year is the year to be most careful, because more people will seek out this medicine, more retreat centers will open, and the gap between the most rigorous and the most casual settings will widen before it narrows.
A CLOSING THOUGHT
Respect for the medicine includes respect for the heart.
I have great respect for what iboga does for people. I have witnessed lives turn on a single ceremony. I would not write any of this if I did not also believe that the medicine is worth the careful preparation it asks of us.
But respect for a medicine includes respect for what it asks of your body. Ibogaine asks something of your heart that no other psychedelic asks in the same way. You — and the facilitator who is going to sit with you — should both be able to answer for it before you begin.
If the answers are clear, the science says you can sit safely. If the answers are vague, please pause. Your heart is irreplaceable. The medicine will still be there when you are ready.
For more on iboga as a medicine, see the iboga medicine page. For the broader harm reduction frame this article sits within, see the harm reduction principles on this site.
SOURCES & FURTHER READING
The science behind this piece.
All citations link to peer-reviewed sources, regulatory documents, and government health agencies where possible.
Cardiac safety and pharmacology
- Ibogaine: Therapeutic Potential, Cardiac Safety, and Translational Perspectives in the Treatment of Substance Use Disorders — A Scoping Review (2026). Molecules.
- Brunt et al., Rare but relevant: Ibogaine and cardiovascular complications — prolonged QT interval and ventricular arrhythmias (2024). Addiction.
- The Anti-Addiction Drug Ibogaine and the Heart: A Delicate Relation — PMC.
- Oxa-Iboga alkaloids lack cardiac risk and disrupt opioid use in animal models — Nature Communications.
- CredibleMeds QTdrugs list — the standard public registry of QT-prolonging medications.
Clinical context and the executive order
- Executive Order: Accelerating Medical Treatments for Serious Mental Illness (April 18, 2026). The White House.
- Trump signs order fast-tracking review of psychedelics for mental health disorders (April 2026). NPR.
- FDA moves to fast-track review of psilocybin and methylone for mental health (April 24, 2026). CNN.
- The Psychedelics Executive Order: Priority Review Vouchers, Ibogaine’s Cardiac Shadow, and the Road Ahead (2026). Frier Levitt.
- Ibogaine for Psychiatric Illness: Federal Policy Push Meets Safety Concerns (2026). Medscape.
- DEA Boosts Legal Production Levels for Psychedelics in Final Rule for 2026 — Marijuana Moment.